A review has indicated endoscopic management options for GERD1
| Radiofrequency Treatment for GERD or Stretta1 |
|
|
 |
|
|
| Transoral Incisionless Fundoplication1 |
 |
|
|
Decreases postprandial TLESRs and EGJ distensibility1 |
|
Minimizes gas bloat as a side effect1 |
|
Is a promising alternative to LNF for rGERD1 |
 |
 |
With BMI <35 kg/m2 1 |  |
Do not respond to PPI1 |  |
With HH <2 cm or HH >2 cm if laparoscopy reduces it to ≤2 cm1 |
 |
With Hill grade I or II classification1 |
 |
 |
Minimally invasive approach with shorter recovery times1 |  |
Decreases PPI usage, and has high patient satisfaction1 |
 |
Significantly reduces RSI scores at 6- and 12-month follow-ups1 |  |
Consistently improves GERD-related symptoms and QoL1 |
| Concomitant Transoral Incisionless Fundoplication1 |
 |
|
 |
Patients who can benefit:1
|
 |
For GERD patients with HH >2 cm:1
|
| Additional Endoscopic Treatment Options1 |
 |
Mucosal ablation of GEJ with APC followed by endoscopic full-thickness suturing enables >50% of patients to discontinue PPIs1 |
| ARMS: Safe and improved symptoms in ~67% of patients with decreased PPI use. Also helpful for GEFV grades II, III and IV1 |  |
 |
RAP: Improves GERD-HRQoL with low side effect profile1 |
| ARBM: Reduces DeMeester scores, acid exposure time, and eventual cessation of PPI therapy within 4 weeks1 |  |
| GERD is a spectrum disorder needing diverse treatments. Endoscopic strategies fit within this spectrum, offering advantages over conventional LARS in an optimized plan.1 |
 |
 |
Vono-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
